About: Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
Creator	Fontanet, Arnaud Schwartz, Olivier Bruel, Timothée Rey, David Fafi-Kremer, Samira Charneau, Pierre Grant, Rebecca Hoen, Bruno Staropoli, Isabelle Anna, François Bolle, Alexandre Collongues, Nicolas De Seze, Jérôme Grzelak, Ludivine Lefebvre, Nicolas Madec, Yoann Meyer, Nicolas Mielcarek, Marie Schmidt-Mutter, Catherine Souque, Philippe Tondeur, Laura Velay, Aurélie
Source	MedRxiv
abstract	Background: The serologic response of individuals with mild forms of SARS-CoV-2 infection is poorly characterized. Methods: Hospital staff who had recovered from mild forms of PCR-confirmed SARS-CoV-2 infection were tested for anti-SARS-CoV-2 antibodies using three assays: a LuLISA targeting the N protein (99% specificity), a rapid immunodiagnostic test (99.4% specificity), and a S- Flow assay (>99.5% specificity). The neutralizing activity of the sera was tested with a pseudovirus-based assay. Results: Of 162 hospital staff who participated in the investigation, 160 reported SARS-CoV- 2 infection that had not required hospital admission and were included in these analyses. The median time from symptom onset to blood sample collection was 24 days (IQR: 21-28, range 13-39). The LuLISA N assay detected antibodies in 129 (80.6%) of the samples, with better performance for samples collected after 28 days (45/48 = 93.8%); the rapid immunodiagnostic test in 153 (95.6%); and the S-Flow assay in 159 (99.4%), failing to detect antibodies in one sample collected 18 days after symptom onset (none of the other tests detected antibodies in that patient). Neutralizing antibodies (NAbs) were detected in 79%, 92% and 98% of samples collected 13-20, 21-27 and 28-41 days after symptom onset, respectively (P=0.02). Conclusion: Antibodies against SARS-CoV-2 were detected in virtually all hospital staff after 13 days from the COVID-19 symptom onset. This finding supports the use of serologic testing for the diagnosis of individuals who have recovered from SARS-CoV-2 infection. The neutralizing activity of the antibodies increased overtime. Future studies will help assess the persistence of the humoral response and its associated neutralization capacity in recovered patients.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1101/2020.05.19.20101832
has license	medrxiv
sha1sum (hex)	5b6020d44b406b856ea26326d2e1763925050bf9
schema:url	https://doi.org/10.1101/2020.05.19.20101832
resource representing a document's title	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
resource representing a document's body	covid:5b6020d44b406b856ea26326d2e1763925050bf9#body_text
is schema:about of	named entity 'Serologic' named entity 'responses' named entity 'individuals' named entity 'disease' named entity 'Serologic' named entity 'SARS-CoV-2' named entity 'France' named entity 'medRxiv' named entity 'medRxiv' named entity 'serologic' named entity 't-test' named entity 'luciferase' named entity 'health care' named entity 'copyright holder' named entity 'ClinicalTrials.gov' named entity 'Antibody' named entity 'serum' named entity 'informed consent' named entity 'epidemic' named entity 'Stata' named entity 'Middle East Respiratory Syndrome' named entity 'SARS-CoV-1' named entity 'COVID' named entity 'antibodies' named entity 'antibody' named entity 'SARS-CoV-2' named entity 'antibodies' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'serological' named entity 'statistically significant' named entity 'preprint' named entity 'medRxiv' named entity 'immunodiagnostic' named entity 'lentiviral' named entity 'seropositive' named entity 'human coronavirus' named entity 'risk factors' named entity 'medRxiv' named entity 'copyright holder' named entity 'SARS-CoV-2' named entity 'ethical approval' named entity 'peer review' named entity 'medical conditions' named entity 'epidemic' named entity 'PCR' named entity 'antibodies' named entity 'medical conditions' named entity 'antibodies' named entity 'IgG' named entity 'IgM antibodies' named entity 'preprint' named entity 'neutralizing antibodies' named entity 'infection' named entity 'Seropositivity' named entity 'infection' named entity 'spike protein' named entity 'serum samples' named entity 'Logistic regression' named entity 'preprint' named entity 'public health' named entity 'medRxiv' named entity 'medical students'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software